Jiayuan Wu1, Liren Hu2, Fenping Wu3, Taiping He4. 1. Department of Nutritional, The Affiliated Hospital of Guangdong Medical College Zhanjiang, Guangdong Province, China. 2. Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical College Zhanjiang, Guangdong Province, China. 3. Department of Radiotherapy, The Seventh People's Hospital of Chengdu, The Oncology Hospital of Chengdu Chengdu, Sichuan Province, China. 4. School of Public Health, Guangdong Medical College Dongguan, Guangdong Province, China.
Abstract
PURPOSE: Recent studies have investigated remodeling and spacing factor 1 (Rsf-1) as a molecular marker in various solid tumors. However, whether or not Rsf-1 exerts a negative or positive effect on the survival of patients with solid cancers remains controversial. Therefore, this study aims to determine whether or not Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression. METHODS: We conducted a meta-analysis of 11 cohort studies (n = 1620 patients) to evaluate the relationship between Rsf-1 and clinical outcome. We included studies with data on overall survival (OS), disease-specific survival (DSS), recurrent-free survival (RFS), metastasis-free survival (MFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: High Rsf-1 expression was significantly associated with poor survival in solid tumors. Overall, the combined HR for OS was 1.49 (95% CI = 1.21-1.84, P < 0.001), DSS 3.07 (95% CI = 1.67-5.62, P < 0.001), RFS 2.51 (95% CI = 1.12-5.63, P = 0.025), and MFS 2.14 (95% CI = 1.49-3.06, P < 0.001). In addition, Rsf-1 overexpression was significantly associated with tumor stage (OR = 4.13, 95% CI = 2.84-6.00, P < 0.001), primary tumor (OR = 2.09, 95% CI = 1.58-2.75, P < 0.001), nodal status (OR = 1.95, 95% CI = 1.40-2.72, P < 0.001), and histological grade (OR = 3.09, 95% CI = 2.10-4.54, P < 0.001). CONCLUSIONS: Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression.
PURPOSE: Recent studies have investigated remodeling and spacing factor 1 (Rsf-1) as a molecular marker in various solid tumors. However, whether or not Rsf-1 exerts a negative or positive effect on the survival of patients with solid cancers remains controversial. Therefore, this study aims to determine whether or not Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression. METHODS: We conducted a meta-analysis of 11 cohort studies (n = 1620 patients) to evaluate the relationship between Rsf-1 and clinical outcome. We included studies with data on overall survival (OS), disease-specific survival (DSS), recurrent-free survival (RFS), metastasis-free survival (MFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: High Rsf-1 expression was significantly associated with poor survival in solid tumors. Overall, the combined HR for OS was 1.49 (95% CI = 1.21-1.84, P < 0.001), DSS 3.07 (95% CI = 1.67-5.62, P < 0.001), RFS 2.51 (95% CI = 1.12-5.63, P = 0.025), and MFS 2.14 (95% CI = 1.49-3.06, P < 0.001). In addition, Rsf-1 overexpression was significantly associated with tumor stage (OR = 4.13, 95% CI = 2.84-6.00, P < 0.001), primary tumor (OR = 2.09, 95% CI = 1.58-2.75, P < 0.001), nodal status (OR = 1.95, 95% CI = 1.40-2.72, P < 0.001), and histological grade (OR = 3.09, 95% CI = 2.10-4.54, P < 0.001). CONCLUSIONS:Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression.
Authors: Angela Bik-Yu Hui; Yvonne Yan-Yan Or; Hirokuni Takano; Raymond King-Yin Tsang; Ka-Fai To; Xin-Yuen Guan; Jonathan Shun-Tong Sham; Katherine Wing-Ki Hung; Cleo Nga-Yee Lam; Charles Andrew van Hasselt; Wen-Lin Kuo; Joe W Gray; Dolly P Huang; Kwok-Wai Lo Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701